Data files

Summary statistics from GWAMA of PCSK9 levels. These data are intended for research purposes only, and available upon publication. For any enquiries about the datasets, please contact Janne Pott (janne.pott@imise.uni-leipzig.de) or Markus Scholz (markus.scholz@imise.uni-leipzig.de).

Citation: tba

When using this data acknowledge the source as follows: 'Data on PCSK9 has been downloaded from https://www.health-atlas.de/data_files/551'

We make three data sets available:

1. Containing statistics ...

We performed gene-expression profiling using Affymetrix U133A GeneChips with RNA from 220 mature aggressive B-cell lymphomas, including a core group of 8 Burkitt's lymphomas that met all World Health Organization (WHO) criteria. A molecular signature for Burkitt's lymphoma was generated, and chromosomal abnormalities were detected with interphase fluorescence in situ hybridization and array-based comparative genomic hybridization.

Molecular profiling of cerebral gliomas distinguishes biologically distinct tumor groups and provides prognostically relevant information beyond histological classification and IDH1/2 mutation status. We performed microarray-based genome- and transcriptome-wide molecular profiling of primary tumor samples from 137 patients with cerebral gliomas, 61 WHO grade II and 76 WHO grade III tumors.

We performed gene-expression profiling using Affymetrix U133A GeneChips with RNA from 873 biopsy specimens including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt’s lymphoma (BL), mixed FL/DLBCL lymphomas, primary mediastinal large B-cell lymphoma (PMBL), multiple myeloma (MM), IRF4-rearranged large cell lymphoma, MYC-negative high-grade B-cell lymphomas with Chr. 11q aberration pattern (mnBLL-11q), and Mantle cell lymphoma (MCL).